![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/spacer.gif) |
¿Preguntas sobre el cáncer?
![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/spacer.gif)
|
1-800-422-6237
(1-800-4-CANCER)
|
![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/spacer.gif)
|
Llame de lunes a viernes de 9:00 a.m. a 4:30 p.m., hora local en Estados Unidos y sus territorios. |
|
![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/spacer.gif)
| Anticuerpo monoclonal que se une a las células que tienen el antígeno CD30 en sus superficies, como las células de la enfermedad de Hodgkin y las células del linfoma anaplásico de células grandes, y del linfoma cutáneo de células T. El SGN-30 está en estudio para el tratamiento del cáncer. Es un tipo de anticuerpo monoclonal. |
![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081105134530im_/http://www.nci.nih.gov/images/spacer.gif) |